R

Research Institute of Dallas | Dallas, TX

Research site
(Unclaimed)
Location
10260 N Central Expressway, Suite 100 N, Dallas, Texas, United States of America
Site insights

Top conditions

Diabetes Mellitus (22 trials)

Type 1 Diabetes Mellitus (12 trials)

Type 2 Diabetes Mellitus (10 trials)

Acromegaly (5 trials)

Syndrome (4 trials)

Top treatments

Empagliflozin
Bococizumab
Dapagliflozin
Tirzepatide
Teplizumab
Metformin
Octreotide
BMS-512148
Paltusotine
LY3298176

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

7 of 43
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW)

The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 dia...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participa...

Active, not recruiting
Diabetes
Type 1 Diabetes
Drug: Insulin Degludec
Drug: Insulin Efsitora Alfa

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weig...

Active, not recruiting
Overweight
Obesity
Drug: Tirzepatide
Drug: Placebo

The purpose of this trial is to assess the long-term safety and efficacy of CAM2029 in patients with acromegaly. Patients will be administered CAM202...

Active, not recruiting
Acromegaly
Drug: CAM2029 (octreotide subcutaneous depot)

The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on to...

Active, not recruiting
Chronic Kidney Disease
Drug: Matching placebo
Drug: Empagliflozin

The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi...

Active, not recruiting
Prader-Willi Syndrome
Drug: DCCR

Trial sponsors

Boehringer Ingelheim logo

Boehringer Ingelheim (5 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems